SHERBORN, MA, CXL Ophthalmics, a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced it has raised a $32 million Series A funding round.
CXL Ophthalmics Scores $32M Series A Round
SHERBORN, MA, CXL Ophthalmics, a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced it has raised a $32 million Series A funding round.
